Epic Sciences and USC Michelson Center Partner to Improve Cancer Care
The exclusive partnership of Epic Sciences, Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience enables the expansion of Epic Sciences’ Liquid Biopsy CTC platform to inform cancer patient care.
"We are excited about this collaboration with Epic Sciences intended to accelerate our goals towards improved cancer patient outcomes." - Dr. Peter Kuhn
The USC Michelson Center for Convergent Bioscience and Epic Sciences, Inc. will work in concert to create more precise characterization of rare circulating tumor cells. Epic is developing a method for liquid-biopsy diagnostics used to characterize a patient’s cancer, which will ultimately help patients and their doctors make better informed treatment decisions.
Peter Kuhn, Ph.D., a founding member of the University of Southern California’s Michelson Center and who leads USC’s Convergent Science Institute in Cancer, says "[This] collaboration with Epic Sciences advances both of our missions.”
Epic plans to offer this next-generation CTC technology as part of its suite of Comprehensive Cancer Profiling™ technologies.